Results 21 to 30 of about 25,328 (173)

Predictive value of post‐treatment C‐reactive protein‐to‐albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy

Thoracic Cancer, 2022
Backgrounds The PACIFIC trial established durvalumab consolidation therapy after concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non–small cell lung cancer (LA‐NSCLC).
Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu, Kei Sonehara, Satoshi Wasamoto, Shigeru Koyama, Fumiaki Yoshiike, Mineyuki Hama, Kenichi Nishie, Daichi Kondo, Toshihiko Agatsuma, Akane Kato, Munetake Takata, Shintaro Kanda, Masayuki Hanaoka, Tomonobu Koizumi   +15 more
doaj   +1 more source

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Radiation Oncology, 2022
Background Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC).
Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata   +12 more
doaj   +1 more source

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study

Vaccines, 2021
Background: The experience of using consolidation durvalumab in post-concurrent chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in real-world clinical practice, and the factors associated with its efficacy are also
Chin-Chou Wang, Li-Chung Chiu, Jia-Shiuan Ju, Yu-Ching Lin, Yueh-Fu Fang, Cheng-Ta Yang, Ping-Chih Hsu   +6 more
doaj   +1 more source

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

Current Oncology, 2023
Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup.
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara Melosky   +11 more
doaj   +1 more source

Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment

Endocrinology, Diabetes & Metabolism Case Reports, 2019
Durvalumab, a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules, is increasingly used in advanced neoplasias.
Jose León Mengíbar, Ismael Capel, Teresa Bonfill, Isabel Mazarico, Laia Casamitjana Espuña, Assumpta Caixàs, Mercedes Rigla   +6 more
doaj   +1 more source

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report

BMC Neurology, 2022
Background Longitudinal extensive transverse myelitis is a rare and potentially life-threatening complication of chemoradiation. Certain chemotherapy agents have been proposed to increased neurotoxicity with chemoradiation therapy.
Travis Moodie, Ola Alshaqi, Abdul Alchaki   +2 more
doaj   +1 more source

Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy

Thoracic Cancer, 2023
Background Patients with locally advanced, unresectable, non‐small cell lung cancer (NSCLC) receiving definitive concurrent chemoradiation therapy (CCRT) benefit from durvalumab consolidation therapy.
Jung Hyun Nam, Chang Dong Yeo, Chan Kwon Park, Sung Kyoung Kim, Ju Sang Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Kim, Sang Haak Lee, Hye Seon Kang   +9 more
doaj   +1 more source

Single‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models

Advanced Science, EarlyView.
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu, Ling Li, Sachin S. Surwase, Xin Ming M. Zhou, Hongtao Qian, Joel C. Sunshine, Florin M. Selaru, Jordan J. Green   +7 more
wiley   +1 more source

Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies

Frontiers in Pharmacology, 2023
Background: The current review aimed to pool real-world evidence on the efficacy and toxicity of consolidation durvalumab for stage III unresectable non-small cell lung cancer (NSCLC) after curative chemoradiotherapy.Methods: PubMed, CENTRAL ...
Yatong Zhang, Yatong Zhang, Yatong Zhang, Yatong Zhang, Yumei Tian, Li Zheng, Li Zheng, Xuelin Sun, Xuelin Sun, Xuelin Sun, Zinan Zhao, Zinan Zhao, Zinan Zhao, Yujing Zheng, Yujing Zheng, Yujing Zheng, Jinhui Tian   +16 more
doaj   +1 more source

A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints

Advanced Science, EarlyView.
ARESEC is a synthetic platform that reconstructs functional V(D)J recombination in HEK293T cells. By introducing RSS elements and co‐expressing RAG1/2 and TdT across all three antibody CDRs, it enables programmable junctional diversification and direct generation of high‐affinity variants targeting PD‐1/PD‐L1, overcoming the evolutionary constraints of
Wang Liu, Jun Yang, Yuhang Zhang, Xiaoli Xue   +3 more
wiley   +1 more source